Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/5d/2a/05/5d2a05d6-9e8f-ebde-5b02-4e7f17c31d76/mza_720905515349598464.jpg/600x600bb.jpg

Foundation Fighting Blindness

238 episodes

2 weeks ago

The Foundation funded preclinical studies for the approach and launched Opus.

All content for Foundation Fighting Blindness is the property of Foundation Fighting Blindness and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

The Foundation funded preclinical studies for the approach and launched Opus.

Science

https://i1.sndcdn.com/avatars-YaeofrSuCwcgCMse-dnoERw-original.jpg

Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy

Foundation Fighting Blindness

1 minute 43 seconds

4 months ago

Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy

The therapy delivers copies of the RORA gene to address multiple disease pathways.